Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan) , gastrointestinal (GI) , or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
Yao, J.C.; Strosberg, J.; Fazio, N.; Pavel, M.E.; Ruszniewski, P.; Bergsland, E.; Li, D.; Tafuto, S.; Raj, N.; Campana, D.; Hijioka, S.; Raderer, M.; Guimbaud, R.; Gajate, P.; Pusceddu, S.; Reising, A.; Degtyarev, E.; Mookerjee, B.; Aimone, P.; Singh, S.
Annals of Oncology Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 467-Viii 468
2018
ISSN/ISBN: 0923-7534 PMID: 32137198 DOI: 10.1093/annonc/mdy293.001
Accession: 069883923
PDF emailed within 0-6 h: $19.90
Related References
Oberg, K. 2009: Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors) Current Opinion in Endocrinology Diabetes and Obesity 16(1): 72-78Wang, Y.; Wang, W.; Jin, K.; Fang, C.; Lin, Y.; Xue, L.; Feng, S.; Zhou, Z.; Shao, C.; Chen, M.; Yu, X.; Chen, J. 2017: Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors Oncology Letters 13(3): 1165-1174
Koumarianou, A.; Pectasides, D.G.; Manousou, K.; Dionysopoulos, D.; Kaltsas, G.A.; Kolomodi, D.; Poulios, C.; Skondra, M.; Samantas, E.; Pentheroudakis, G.; Fountzilas, G. 2018: Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors Annals of Oncology: Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 475
Sorbye, H.; Baudin, E.; Perren, A. 2018: The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond Endocrinology and Metabolism Clinics of North America 47(3): 683-698
Bombardieri, E.; Seregni, E.; Savelli, G.; Villano, C.; Castellani, M.R.; Cirillo, F.; Pallotti, F.; Fracassi, S.; Chiesa, C.; Chiti, A.; Bajetta, E. 2003: Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors Journal of endocrinological investigation 26(8 Suppl): 63-69
Yalcin, S.; Bayram, F.; Erdamar, S.; Kucuk, O.; Oruc, N.; Coker, A. 2017: Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up Archives of Medical Science: Ams 13(2): 271-282
Raj, N.; Fazio, N.; Strosberg, J. 2018: Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 38: 292-299
Holmager, P.; Langer, S.W.; Kjaer, A.; Ringholm, L.; Garbyal, R.S.; Pommergaard, H.-C.; Hansen, C.P.æs.; Federspiel, B.; Andreassen, M.; Knigge, U. 2022: Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms Current Treatment Options in Oncology 23(6): 806-817
Fan, M.; Yan, H.; Gou, M.; Qian, N.; Dai, G. 2020: Divergent expression of DCLK1 in gastrointestinal neuroendocrine tumors and primary hepatic, gallbladder, and pancreatic neuroendocrine tumors International Journal of Clinical and Experimental Pathology 13(9): 2249-2258
Allaw, M.B.; Switchenko, J.M.; Khalil, L.; Wu, C.; Alese, O.B.; Akce, M.; Draper, A.; Jones, A.T.; El-Rayes, B.; Shaib, W. 2022: Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors Oncology 100(3): 131-139
Simon, T.; Riemer, P.; Jarosch, A.; Detjen, K.; Di Domenico, A.; Bormann, F.; Menne, A.; Khouja, S.; Monjé, N.; Childs, L.H.; Lenze, D.; Leser, U.; Rossner, F.; Morkel, M.; Blüthgen, N.; Pavel, M.; Horst, D.; Capper, D.; Marinoni, I.; Perren, A.; Mamlouk, S.; Sers, C. 2022: DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors Genome Medicine 14(1): 24
Uri, I.; Grozinsky-Glasberg, S. 2018: Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Clinical Diabetes and Endocrinology 4: 16
Rose, D.B.; Nellesen, D.; Neary, M.P.; Cai, B. 2017: Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic Journal of Medical Economics 20(4): 395-404
Van Vliet, E.I.; Krenning, E.P.; Teunissen, J.J.; Bergsma, H.; Kam, B.L.; Kwekkeboom, D.J. 2013: Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate Journal of Nuclear Medicine: Official Publication Society of Nuclear Medicine 54(10): 1689-1696
Lee, L.; Igarashi, H.; Hijioka, M.; Ueda, K.; Fujiyama, T.; Tachibana, Y.; Kawabe, K.; Ito, T. 2015: Sa2048 Efficacy and Safety of Everolimus As Long-Term Treatment in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors Gastroenterology 148(4): S-393
Saglam, S.; Hacisahinogullari, H.; Ozturk, N.; Kapran, Y.; Gulluoglu, M.; Turkmen, C.; Adalet, I.; Orhan Bilge, A.; Cem Balci, N. 2015: Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors Journal of BUON: Official Journal of the Balkan Union of Oncology 20(5): 1201-1205
Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G. 2015: 5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study European Journal of Cancer 51: S709-S710
Klöppel, Günter.; Couvelard, A.; Perren, A.; Komminoth, P.; McNicol, A-Marie.; Nilsson, O.; Scarpa, A.; Scoazec, J-Yves.; Wiedenmann, B.; Papotti, M.; Rindi, G.; Plöckinger, U.; Akerström, Göran.; Annibale, B.; Arnold, R.; Bajetta, E.; Barkmanova, J.; Chen, Y-Jia.; Costa, F.; Davar, J.; de Herder, W.; Delle Fave, G.; Eriksson, B.; Falconi, M.; Ferone, D.; Gross, D.; Grossman, A.; Gustafsson, Börn.; Hyrdel, R.; Ivan, D.; Kaltsas, G.; Kianmanesh, R.; Knigge, U-Peter.; Kos-Kudła, B.; Kwekkeboom, D.; Lebtahi, R.; Lewington, V.; Mitry, E.; Oberg, K.; O'Connor, J.; O'Toole,; 2009: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification Neuroendocrinology 90(2): 162-166
Sangoi, A.R.; Ohgami, R.S.; Pai, R.K.; Beck, A.H.; McKenney, J.K.; Pai, R.K. 2011: PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 24(3): 412-424
Worth, P.J.; Leal, J.; Ding, Q.; Trickey, A.; Dua, M.M.; Chatzizacharias, N.; Soonawalla, Z.; Athanasopoulos, P.; Toumpanakis, C.; Hansen, P.; Parks, R.W.; Connor, S.; Parker, K.; Koea, J.; Srinavasa, S.; Ielpo, B.; Vicente Lopez, E.; Lawrence, B.; Visser, B.C. 2020: Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions Hpb: the Official Journal of the International Hepato Pancreato Biliary Association 22(9): 1359-1367